Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives

Dysregulation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin signaling is common in both indolent and aggressive forms of malignant lymphoma, for which several targeted therapies have been developed. Copanlisib is a highly selective and potent intravenous pan-...

Descripción completa

Detalles Bibliográficos
Autores principales: Munoz, Javier, Follows, George A., Nastoupil, Loretta J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941125/
https://www.ncbi.nlm.nih.gov/pubmed/33687623
http://dx.doi.org/10.1007/s11523-021-00802-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941125/
https://www.ncbi.nlm.nih.gov/pubmed/33687623
http://dx.doi.org/10.1007/s11523-021-00802-9

Ejemplares similares